The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

According to Novo Nordisk, over 40% of persons with type 2 diabetes have chronic renal disease, which affects roughly 37 ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

TNF Pharmaceuticals (TNFA), announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha ...

The first study examines TNF-a levels in patients receiving the GLP-1 agonist Wegovy ® or Ozempic ® who show signs of increased inflammation associated with sarcopenia, which is the progressive loss ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...

Clinics in Columbus, Cleveland, Dayton, and Cincinnati have lost their licenses to distribute dangerous drugs after the Ohio ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisks (NYSE:NVO) Ozempic for reducing the risk of kidney ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...